Selective and potent BACE-1 inhibitorsoffer promising therapeutic avenues for Alzheimer’s disease.While BACE-1 inhibitors have shown significant assurance as potentialtreatments for Alzheimer’s disease, many early compounds struggledto advance clinically due to poor brain penetration, limited selectivity,and unwanted side effects. The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.